These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21813613)

  • 1. Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.
    Koh Y; Aoki M; Danish ML; Aoki-Ogata H; Amano M; Das D; Shafer RW; Ghosh AK; Mitsuya H
    J Virol; 2011 Oct; 85(19):10079-89. PubMed ID: 21813613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.
    Aoki M; Das D; Hayashi H; Aoki-Ogata H; Takamatsu Y; Ghosh AK; Mitsuya H
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.
    Hayashi H; Takamune N; Nirasawa T; Aoki M; Morishita Y; Das D; Koh Y; Ghosh AK; Misumi S; Mitsuya H
    Proc Natl Acad Sci U S A; 2014 Aug; 111(33):12234-9. PubMed ID: 25092296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.
    Koh Y; Amano M; Towata T; Danish M; Leshchenko-Yashchuk S; Das D; Nakayama M; Tojo Y; Ghosh AK; Mitsuya H
    J Virol; 2010 Nov; 84(22):11961-9. PubMed ID: 20810732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
    Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
    J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease.
    Louis JM; Tözsér J; Roche J; Matúz K; Aniana A; Sayer JM
    Biochemistry; 2013 Oct; 52(43):7678-88. PubMed ID: 24079831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
    Lambert-Niclot S; Flandre P; Canestri A; Peytavin G; Blanc C; Agher R; Soulié C; Wirden M; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Feb; 52(2):491-6. PubMed ID: 18039922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.
    Aoki M; Danish ML; Aoki-Ogata H; Amano M; Ide K; Das D; Koh Y; Mitsuya H
    J Virol; 2012 Dec; 86(24):13384-96. PubMed ID: 23015723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
    Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity.
    Bulut H; Hattori SI; Aoki-Ogata H; Hayashi H; Das D; Aoki M; Davis DA; Rao KV; Nyalapatla PR; Ghosh AK; Mitsuya H
    Sci Rep; 2020 Jun; 10(1):10664. PubMed ID: 32606378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
    Koh Y; Matsumi S; Das D; Amano M; Davis DA; Li J; Leschenko S; Baldridge A; Shioda T; Yarchoan R; Ghosh AK; Mitsuya H
    J Biol Chem; 2007 Sep; 282(39):28709-28720. PubMed ID: 17635930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.
    Eche S; Kumar A; Sonela N; Gordon ML
    Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33805099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
    Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resistance to darunavir].
    García Deltoro M
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():51-60. PubMed ID: 19195460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
    Mittal S; Bandaranayake RM; King NM; Prabu-Jeyabalan M; Nalam MN; Nalivaika EA; Yilmaz NK; Schiffer CA
    J Virol; 2013 Apr; 87(8):4176-84. PubMed ID: 23365446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Protease Inhibitors Containing C-5-Modified
    Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structures of darunavir-resistant HIV-1 protease mutant reveal atypical binding of darunavir to wide open flaps.
    Zhang Y; Chang YC; Louis JM; Wang YF; Harrison RW; Weber IT
    ACS Chem Biol; 2014 Jun; 9(6):1351-8. PubMed ID: 24738918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance profile of darunavir: combined 24-week results from the POWER trials.
    de Meyer S; Vangeneugden T; van Baelen B; de Paepe E; van Marck H; Picchio G; Lefebvre E; de Béthune MP
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):379-88. PubMed ID: 18327986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.